US Biosimilar Fee Collections Fall Short
The FDA Has Modified Its Carryover Spend-Down Plan
Executive Summary
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.
You may also be interested in...
US FDA Reports Millions In Unpaid GDUFA Program Fees
The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.
User Fee Delinquencies Rising At US FDA After PDUFA Redesign
Prescription drug user fee "receivables" nearly doubled in FY 2018, but the US FDA is not worried.
Biosimilars: Rise In US FDA Approvals Means Lower Or Flat User Fees In FY 2020
Fees for applications and approved products will stay the same, while product development levies will fall 36%, the FDA announces. The agency’s biosimilar activities are becoming more reliant on funding from the growing number of products approved and less on those still in development.